Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Objectives: This phase III trial asks whether the addition of temozolomide (Temodar) to radiation therapy can improve progression-free survival and/or overall survival of patients with grade 2 glioma at the most recent pathological diagnosis.

Key entry or exclusion criteria: Patients with a previous pathological diagnosis of grade 3 or 4 are excluded, as are patients with prior radiotherapy, cytotoxic chemotherapy, radiosurgery, or investigational therapy for the brain tumor. Prior surgery is permitted.

Locations: 173 sites

Goal: 540 patients

Study sponsor: Eastern Cooperative Oncology Group in collaboration with the National Cancer Institute.

Link for more information: clinicaltrials.gov/ct2/show/study/NCT00978458

NIH clinical trials identifier: NCT00978458